Skip to main content

Generic Verkazia Availability

Last updated on Jul 6, 2022.

Verkazia is a brand name of cyclosporine ophthalmic, approved by the FDA in the following formulation(s):

VERKAZIA (cyclosporine - emulsion;ophthalmic)

  • Manufacturer: SANTEN
    Approval date: June 23, 2021
    Strength(s): 0.1% [RLD]

Has a generic version of Verkazia been approved?

No. There is currently no therapeutically equivalent version of Verkazia available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Verkazia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Emulsion compositions containing quaternary ammonium compounds
    Patent 7,973,081
    Issued: July 5, 2011
    Inventor(s): Rabinovich-Guilatti; Laura & Lambert; Gregory & Lallemand; Frederic & Philips; Betty
    Assignee(s): Novagali Pharma SA

    Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.

    Patent expiration dates:

    • January 27, 2026
      ✓ 
      Drug product
  • Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
    Patent 8,298,568
    Issued: October 30, 2012
    Inventor(s): Bague; Séverine & Philips; Betty & Garrigue; Jean-Sébastien & Rabinovich-Guilatt; Laura & Lambert; Gregory
    Assignee(s): Novagali Pharma SA

    A well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.

    Patent expiration dates:

    • November 3, 2027
      ✓ 
      Drug product
  • Emulsion compositions containing quaternary ammonium compounds
    Patent 8,524,779
    Issued: September 3, 2013
    Assignee(s): Novagali Pharma SA

    Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.

    Patent expiration dates:

    • January 27, 2026
      ✓ 
      Drug product
  • Compositions containing quaternary ammonium compounds
    Patent 9,132,071
    Issued: September 15, 2015
    Assignee(s): SANTEN SAS

    Compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, where composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, and the ophthalmic emulsions being are useful for eye care or for the treatment of eye conditions.

    Patent expiration dates:

    • June 2, 2029
      ✓ 
      Drug product
  • Emulsion compositions containing cetalkonium chloride
    Patent 9,220,694
    Issued: December 29, 2015
    Assignee(s): SANTEN SAS

    Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

    Patent expiration dates:

    • January 27, 2026
      ✓ 
      Drug product
  • Emulsion compositions containing quaternary ammonium compounds
    Patent 9,956,289
    Issued: May 1, 2018
    Assignee(s): SANTEN SAS

    Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

    Patent expiration dates:

    • January 27, 2026
      ✓ 
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • June 23, 2023 - NEW PRODUCT
    • June 23, 2028 - FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS (VKC) IN CHILDREN AND ADULTS

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.